Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

34 citing papers in PubMed.

1. Antibody-lectin chimeras for glyco-immune checkpoint blockade.Nature biotechnology · 2026
   Article
2. Inflammation: a matter of immune cell life and death.npj biomedical innovations · 2025
   Review
3. Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma.Proceedings of the National Academy of Sciences of the United States of America · 2025
   Article
4. Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles.ACS applied materials & interfaces · 2020
   Article
5. The role of macrophages during breast cancer development and response to chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
   Review
6. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.Pharmacological research · 2020
   Article
7. The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers.Trends in pharmacological sciences · 2020
   Review
8. Immunotherapy Targeting Tumor-Associated Macrophages.Frontiers in medicine · 2020
   Review
9. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.Science advances · 2019
   Article
10. Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells.Frontiers in oncology · 2019
    Article
11. Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.Paediatric drugs · 2018
    Review
12. Comparative Characterization of Osteoclasts Derived From Murine Bone Marrow Macrophages and RAW 264.7 Cells Using Quantitative Proteomics.JBMR plus · 2018
    Article
13. Targeting tumour microenvironment by tyrosine kinase inhibitor.Molecular cancer · 2018
    Review
14. BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?TH open : companion journal to thrombosis and haemostasis · 2018
    Review
15. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.Cancer letters · 2017
    Article
16. p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli.Aging · 2017
    Article
17. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.Advanced drug delivery reviews · 2017
    Review
18. Targeting tumor-associated macrophages to combat pancreatic cancer.Oncotarget · 2016
    Review
19. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.Clinical lymphoma, myeloma & leukemia · 2016
    Article
20. Bone-targeting agents in prostate cancer.Cancer metastasis reviews · 2014
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as